Cerebrovascular accident prophylaxis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:08:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cerebrovascular accident prophylaxis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke https://clinicaltrials.eu/trial/study-on-asundexian-and-apixaban-for-preventing-stroke-in-adults-with-atrial-fibrillation-at-risk-for-stroke/ Wed, 29 Apr 2026 14:27:01 +0000 https://clinicaltrials.eu/trial/study-on-asundexian-and-apixaban-for-preventing-stroke-in-adults-with-atrial-fibrillation-at-risk-for-stroke/ This clinical trial is focused on studying the prevention of stroke or systemic embolism in people with atrial fibrillation, a condition where the heart beats irregularly and often rapidly. The study is comparing two treatments: asundexian (also known by its code name BAY 2433334) and apixaban, which is marketed under the name Eliquis. Both medications are taken orally in the form of film-coated tablets. The purpose of the study is to determine how well asundexian works and how safe it is compared to apixaban in preventing stroke or systemic embolism in individuals with atrial fibrillation who are at risk for stroke.

Participants in the study will be randomly assigned to receive either asundexian or apixaban. Some participants will receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The trial will last for a period of up to 33 days, during which the safety and effectiveness of the treatments will be closely monitored.

The main goal is to see if asundexian is at least as effective as apixaban in preventing stroke and systemic embolism, and to assess the risk of major bleeding, which is a significant concern with blood-thinning medications. The study will also look at other outcomes, such as the occurrence of minor bleeding, cardiovascular events, and overall mortality. This research aims to provide valuable information on the potential benefits and risks of asundexian compared to apixaban for people with atrial fibrillation at risk of stroke.

]]> Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke https://clinicaltrials.eu/trial/study-on-asundexian-for-preventing-ischemic-stroke-in-adults-after-a-stroke-or-high-risk-mini-stroke/ Wed, 29 Apr 2026 14:26:46 +0000 https://clinicaltrials.eu/trial/study-on-asundexian-for-preventing-ischemic-stroke-in-adults-after-a-stroke-or-high-risk-mini-stroke/ This clinical trial is focused on studying the prevention of ischemic stroke in individuals who have recently experienced an acute non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA), which is often referred to as a mini-stroke. The study is testing a medication called asundexian, also known by its code name BAY 2433334. This medication is being compared to a placebo to see if it can better prevent strokes when used alongside standard antiplatelet therapy, which is a treatment that helps prevent blood clots.

The purpose of the study is to evaluate the effectiveness and safety of asundexian in reducing the risk of ischemic strokes. Participants in the study will be randomly assigned to receive either asundexian or a placebo. The study will monitor the time it takes for participants to experience another ischemic stroke or any major bleeding events, which are significant bleeding episodes that can occur in the body. The trial will also look at other outcomes, such as the occurrence of any type of stroke, heart-related events, and overall survival rates.

Throughout the study, participants will take the medication orally in the form of a film-coated tablet. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, ensuring unbiased results. The study aims to provide valuable information on whether asundexian can offer better protection against strokes compared to current treatments.

]]>